BMY Bristol-Myers Squibb Company - Fundamental Analysis
NEUTRAL
BMY Stock | Fundamental Analysis & Investment Insights
NYSE
•
Healthcare
•
Drug Manufacturers - General
Current Price
$46.65
Analyst Target
$52.73
+13.0% Upside
52W High
$63.33
52W Low
$42.52
AI Analysis
Powered by advanced machine learning algorithms
Confidence Score
72%
Analysis Accuracy
Bristol-Myers Squibb (BMY) trades at a significant discount to peers on valuation with a compelling 5.32% dividend yield and strong profitability, yet faces headwinds from stagnant revenue growth and declining earnings momentum. Despite a robust ROE of 33.78% and gross margins above 73%, YoY EPS has contracted by 40%, raising concerns about post-pandemic commercial execution and pipeline monetization. The stock has underperformed over 3Y (-30.1%) and 1Y (-16.3%) but shows recent stabilization with a +7.0% one-month gain, suggesting potential bottoming. Analysts are tepid with a $52.73 target implying 13% upside, while insider selling—particularly a $2.67M CFO transaction—casts caution on near-term confidence.
Key Strengths
High dividend yield of 5.32% among the highest in the peer group, providing income resilience
Exceptional profitability with ROE of 33.78% and operating margin of 31.57%, well above sector average ROE of 36.77% and peer medians
Attractive valuation at Forward P/E of 6.64 vs sector average of 40.74, suggesting deep discounting
Gross margin of 73.15% reflects pricing power and low cost of goods in branded pharmaceuticals
Analyst target price of $52.73 implies 13% upside, indicating asymmetric risk-reward
Key Risks
Earnings under severe pressure: YoY EPS down 40.0% and Q/Q down 26.0%, signaling structural or execution challenges
Revenue growth of only 2.80% YoY lags sector average of 11.14%, indicating weak top-line momentum
High leverage with Debt/Equity of 2.74, more than double the sector average of 1.06, increasing refinancing and interest rate risk
Insider selling activity, including CFO disposal of 56,000 shares, signals lack of confidence at the executive level
Forward P/E of 6.64, while low, may reflect legitimate concerns about patent cliffs or pipeline delays rather than value opportunity
AI Fair Value Estimate
Based on comprehensive analysis
$52.73
+13.0% above current price
Performance Snowflake
Multi-dimensional AI analysis across 5 key categories
Stock Price & Analyst Targets
Real-time price movements and analyst price targets
Historical Performance Trends
Long-term financial metrics and growth patterns
Valuation Metrics
Key valuation ratios and pricing indicators
Profitability, Growth & Financial Health
Detailed profit margins, ROE, debt ratios, and liquidity metrics
Sector Comparison & Peer Analysis
Compare BMY against industry averages and similar companies
Insider Trading & Analyst Ratings
Track insider transactions and Wall Street analyst recommendations